Investors

We have strong financial and industrial shareholders.

Annual financial statements, quarterly reports and presentations.

Please contact our IR Contacts for any queries.

Long-term results from the clinical study with UV1 in combination with ipilimumab in patients with malignant melanoma presented at the 2020 ASCO-SITC conferance.